Cancer and Aging Resilience Evaluation in Older Adults with Hematologic Malignancies: the CARE-Heme Registry

Launched by UNIVERSITY OF ALABAMA AT BIRMINGHAM · Sep 22, 2022

Keywords

ClinConnect Summary

The CARE-Heme Registry is a clinical trial focused on understanding the health of older adults (age 50 and above) who have specific blood cancers, such as Multiple Myeloma, Amyloidosis, and Plasma Cell Leukemia. The main goal of this study is to gather information about how these patients are coping, particularly looking at issues like frailty and other age-related health challenges. This information will help future research aimed at improving care for older patients with these conditions.

To be eligible for the trial, participants must be at least 50 years old and have been diagnosed with one of the specified blood cancers through a biopsy. They also need to have appointments at the University of Alabama at Birmingham (UAB), either as inpatients or outpatients. Individuals under 50 or those who do not read or speak English will not be able to participate. If someone joins the study, they can expect to provide information through questionnaires that will help researchers better understand the unique needs of older adults facing these types of cancers.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients are ≥50 years of age.
• • Patients have a biopsy proven diagnosis of Hematologic Malignancy (Multiple Myeloma, AL Amyloidosis, Waldenstrom's Macrogloblunemia, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Myelodysplastic syndromes, Myeloproliferative Neoplasm, Acute/Chronic Myeloid Leukemia, Acute/Chronic Lymphoid Leukemia).
• • Patients have appointments at UAB including if they are an inpatient or other clinic locations.
• Exclusion Criteria:
• • Individuals who are \<50 years old.
• • Patients who do not read and/or speak English will not be eligible for this study as many of the questionnaires are not validated in other languages. No exclusions will be made based on gender, ethnicity or race.